Congruence Therapeutics is working at the intersection of several high-growth industries such as structural bioinformatics, computational chemistry, deep sequencing and machine learning that are revolutionizing the drug discovery process. We are deploying an in silico platform that enables the discovery of new pharmaceutical stabilizers, a validated class of small molecules, at an unprecedented speed and scale.
Location: Canada
Employees: 11-50
Total raised: $147M
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.09.2025 | - | $32M | Lumira Ven... |
| 06.03.2023 | Series A | $65M | - |
| 08.02.2022 | Series A | $50M | - |
Mentions in press and media 12
| Date | Title | Description |
| 23.03.2026 | Congruence Therapeutics Raises $39.5M in Funding | Congruence Therapeutics, a Montreal, Canada-based clinical-stage biotechnology company, raised $39.5M in funding. The round was led by Dimension and existing investor OrbiMed with participation from Amplitude Ventures, FSTQ, Lumira, Investi... |
| 12.09.2025 | Congruence Therapeutics: $32 Million Financing Raised For Advancing Genetic Obesity Therapy | Congruence Therapeutics has secured a $32 million financing round to support the development of its lead candidate CGX-926, the first clinical therapy designed to treat MC4R-deficient genetic obesity. The proceeds will fund a Phase 1 trial ... |
| 04.09.2025 | Congruence Therapeutics Raises $32M in Funding | Congruence Therapeutics, a Montreal, Canada-based computationally-driven biotechnology company, raised $32M in funding. The round was led by Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital’s Thrive Venture Fund, OrbiMed... |
| 06.12.2024 | Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area | OSAKA, Japan and MONTREAL , Dec. 6, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with C... |
| 06.03.2023 | Drug discovery startup Congruence Therapeutics closes $20 million CAD extension of Series A | - |
| 06.03.2023 | Congruence Therapeutics Closes Extension Funding; Closes Over US$65M Series A | Congruence Therapeutics, a Montreal, Canada-based biotechnology company working at the interface of computational and experimental drug discovery, raised approx. US$15M in additional Series A funding. The round, which brought the total amou... |
| 06.03.2023 | Congruence Therapeutics Announces Close of Series A Extension, Bringing Total Round to Over US$65 Million | Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the close of an extension to its ... |
| 22.11.2022 | Congruence Therapeutics Strengthens Leadership Team with Appointment of Dr. Sharath Hegde as Chief Scientific Officer | Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced the appointment of Sharath S. Hegde, Ph... |
| 28.02.2022 | Rare Disease Day 2022 | Today is Rare Disease Day and we at Lumira Ventures are proud of our ongoing commitment to supporting the discovery, development and commercialization of innovative therapeutic products with the potential to materially impact the lives of p... |
| 08.02.2022 | Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding | Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the closing of a US$50 million, t... |
Show more